Treatment complications in children diagnosed with neuroblastoma during a screening program

Journal of Clinical Oncology

Volumn 24, Issue 10, 2006, Pages 1542-1545

  Barrette, Stéphane ^a   Bernstein, Mark L ^a   Leclerc, Jean Marie ^a   Champagne, Martin A ^a   Samson, Yvan ^a   Brossurad, Josée ^a   Woods, William G ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CISPLATIN; EPIPODOPHYLLOTOXIN DERIVATIVE; HOMOVANILLIC ACID; VANILMANDELIC ACID;

ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; INFANT; NEUROBLASTOMA; NEWBORN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; MASS SCREENING; MORTALITY; PATHOLOGY; URINE;

HOMOVANILLIC ACID; HUMANS; INFANT; INFANT, NEWBORN; MASS SCREENING; NEOPLASM STAGING; NEUROBLASTOMA; VANILMANDELIC ACID;

EID: 33645739392     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.4602     Document Type: Article

References (15)

1. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review, 1975-2002. Bethesda, MD, National Cancer Institute, 2002
2. Auray-Blais C, Giguere R, Lemieux B: Thin-layer chromatography of urinary homovanillic acid and vanillylmandelic acid for large-scale neuroblastoma mass screening. Med Pediatr Oncol 17:364-367, 1989
3. Tuchman M, Lemieux B, Auray-Blais C, et al: Screening for neuroblastoma at 3 weeks of age: Methods and preliminary results from the Quebec Neuroblastoma Screening Project. Pediatrics 86: 765-773, 1990
4. Woods WG, Tuchman M, Robison LL, et al: A population-based study of the usefulness of screening for neuroblastoma. Lancet 348:1682-1687, 1996
5. Woods WG, Gao RN, Shuster JJ, et al: Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:1041-1046, 2002
6. Brodeur GM, Look AT, Shimada H, et al: Biological aspects of neuroblastomas identified by mass screening in Quebec. Med Pediatr Oncol 36:157-159, 2001
7. Castleberry RP: Biology and treatment of neuroblastoma. Pediatr Clin North Am 44:919-937, 1997
8. Suita S, Tajiri T, Akazawa K, et al: Mass screening for neuroblastoma at 6 months of age: Difficult to justify. J Pediatr Surg 33:1674-1678, 1998
9. Kerbl R, Urban CE, Ambros IM, et al: Neuroblastoma mass screening in late infancy: Insights into the biology of neuroblasts tumors. J Clin Oncol 21:4228-4234, 2003
10. Schilling FH, Spix C, Berthold F, et al: Neuroblastoma screening at one year of age. N Engl J Med 346:1047-1053, 2002
11. Iwanaka T, Yamamoto K, Ogawa Y, et al: Maturation of mass-screened localized adrenal neuroblastoma. J Pediatr Surg 36:1633-1636, 2001
12. Nishihira H, Toyoda Y, Tanaka Y, et al: Natural course of neuroblastoma detected by mass screening: A 5-year prospective study at a single institution. J Clin Oncol 18:3012-3017, 2000
13. Ikeda H, Suzuki N, Takahashi A, et al: Surgical treatment of neuroblastomas in infants under 12 months of age. J Pediatr Surg 33:1246-1250, 1998
14. Kerbl R, Urban CE, Ladenstein R, et al: Neuroblastoma screening of infants postponed after the sixth month of age: A trial to reduce "overdiagnosis" and to detect cases with "unfavorable" biologic features. Med Pediatr Oncol 29:1-10, 1997
15. Fritsch P, Kerbl R, Lackner H, et al: "Wait and see" strategy in localized neuroblastoma in infants: An option not only for cases detected by mass screening. Pediatr Blood Cancer 43:679-682, 2004